Search company, investor...

Predict your next investment

Vision Plus Capital company logo
Venture Capital
vplus.vc

Investments

204

Portfolio Exits

6

Funds

5

About Vision Plus Capital

Vision Plus Capital, aka Yuanjing Capital, is a venture capital firm focused on consumer products & lifestyle, B2B services, life sciences, and financial services.

Headquarters Location

No. 19, Xixi Art Collection Village Fangxi Road, Wuchang Avenue, Yuhang District

Hangzhou, Zhejiang , 310000,

China

+86-571-8873-7970

Want to inform investors similar to Vision Plus Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Vision Plus Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Vision Plus Capital in 1 Expert Collection, including New Retail Formats.

N

New Retail Formats

11 items

Companies offering automated checkout solutions for retailers or operating cashless, cashier-free retail stores.

Latest Vision Plus Capital News

Financing round-up: QuantHealth, Mariana Oncology, Corteria Pharmaceuticals, Innovac Therapeutics

Sep 12, 2023

China: Innovac Therapeutics, an mRNA therapeutics company, has completed a US$18m Series Pre-A financing. The round includes Elikon Venture, Vision Plus Capital, Yunion Healthcare Ventures, TG Sino-Dragon Fund and other industry and private individuals. Proceeds will be used to further develop its technology platform and manufacturing capability to advance its lead programmes to clinical stage. […]

Vision Plus Capital Investments

204 Investments

Vision Plus Capital has made 204 investments. Their latest investment was in Innovac Therapeutics as part of their Seed VC on September 9, 2023.

CBI Logo

Vision Plus Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/1/2023

Seed VC

Innovac Therapeutics

$18M

Yes

Elikon Venture, TG Sino-Dragon Fund, Undisclosed Angel Investors, Undisclosed Investors, Vision Plus Capital, and Yunion Health

1

7/4/2023

Series A

Ujoin-Tech

$13.86M

Yes

2

7/3/2023

Seed VC

LC Computing

$6.9M

Yes

2

6/16/2023

Series A

Subscribe to see more

Subscribe to see more

10

4/6/2023

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/1/2023

7/4/2023

7/3/2023

6/16/2023

4/6/2023

Round

Seed VC

Series A

Seed VC

Series A

Series B

Company

Innovac Therapeutics

Ujoin-Tech

LC Computing

Subscribe to see more

Subscribe to see more

Amount

$18M

$13.86M

$6.9M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Elikon Venture, TG Sino-Dragon Fund, Undisclosed Angel Investors, Undisclosed Investors, Vision Plus Capital, and Yunion Health

Sources

1

2

2

10

10

Vision Plus Capital Portfolio Exits

6 Portfolio Exits

Vision Plus Capital has 6 portfolio exits. Their latest portfolio exit was Zailouxia on January 08, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/8/2022

Acquired

$99M

4

6/25/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2020

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

1/17/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/26/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/8/2022

6/25/2021

5/29/2020

1/17/2020

3/26/2019

Exit

Acquired

IPO

Corporate Majority

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Vision Plus Capital Fund History

5 Fund Histories

Vision Plus Capital has 5 funds, including Vision Plus Capital Fund III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/18/2020

Vision Plus Capital Fund III

Early-Stage Venture Capital

Open

$400M

2

2/25/2020

Vision Plus Capital Growth Fund I

Subscribe to see more

Subscribe to see more

$99M

10

2/13/2018

Vision Plus Capital Fund II

Subscribe to see more

Subscribe to see more

$99M

10

Hangzhou Yuanjing Lok Chi Equity Investment Fund LP

Subscribe to see more

Subscribe to see more

10

Beijing Hulian Yuanjing Venture Capital Investment Center LP

Subscribe to see more

Subscribe to see more

10

Closing Date

3/18/2020

2/25/2020

2/13/2018

Fund

Vision Plus Capital Fund III

Vision Plus Capital Growth Fund I

Vision Plus Capital Fund II

Hangzhou Yuanjing Lok Chi Equity Investment Fund LP

Beijing Hulian Yuanjing Venture Capital Investment Center LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Open

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$400M

$99M

$99M

Sources

2

10

10

10

10

Vision Plus Capital Team

2 Team Members

Vision Plus Capital has 2 team members, including , .

Name

Work History

Title

Status

Miao Miu

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Miao Miu

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.